全文获取类型
收费全文 | 2988篇 |
免费 | 334篇 |
国内免费 | 97篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 13篇 |
妇产科学 | 62篇 |
基础医学 | 710篇 |
口腔科学 | 31篇 |
临床医学 | 189篇 |
内科学 | 391篇 |
皮肤病学 | 136篇 |
神经病学 | 185篇 |
特种医学 | 41篇 |
外国民族医学 | 1篇 |
外科学 | 156篇 |
综合类 | 134篇 |
现状与发展 | 5篇 |
预防医学 | 22篇 |
眼科学 | 34篇 |
药学 | 257篇 |
3篇 | |
中国医学 | 8篇 |
肿瘤学 | 1023篇 |
出版年
2024年 | 22篇 |
2023年 | 236篇 |
2022年 | 371篇 |
2021年 | 444篇 |
2020年 | 355篇 |
2019年 | 249篇 |
2018年 | 160篇 |
2017年 | 152篇 |
2016年 | 95篇 |
2015年 | 98篇 |
2014年 | 83篇 |
2013年 | 113篇 |
2012年 | 70篇 |
2011年 | 75篇 |
2010年 | 68篇 |
2009年 | 67篇 |
2008年 | 87篇 |
2007年 | 65篇 |
2006年 | 53篇 |
2005年 | 44篇 |
2004年 | 60篇 |
2003年 | 39篇 |
2002年 | 31篇 |
2001年 | 30篇 |
2000年 | 20篇 |
1999年 | 30篇 |
1998年 | 23篇 |
1997年 | 24篇 |
1996年 | 22篇 |
1995年 | 16篇 |
1994年 | 20篇 |
1993年 | 18篇 |
1992年 | 11篇 |
1991年 | 14篇 |
1990年 | 14篇 |
1989年 | 9篇 |
1988年 | 5篇 |
1987年 | 19篇 |
1986年 | 14篇 |
1985年 | 17篇 |
1984年 | 13篇 |
1983年 | 8篇 |
1982年 | 13篇 |
1981年 | 12篇 |
1980年 | 7篇 |
1979年 | 3篇 |
1978年 | 5篇 |
1977年 | 4篇 |
1976年 | 5篇 |
1973年 | 5篇 |
排序方式: 共有3419条查询结果,搜索用时 31 毫秒
1.
《Cancer cell》2022,40(3):318-334.e9
- Download : Download high-res image (268KB)
- Download : Download full-size image
2.
3.
Barouyr Baroudjian Dimitri Arangalage Stefania Cuzzubbo Baptiste Hervier Celeste Lebbé Gwenael Lorillon 《Expert review of anticancer therapy》2019,19(3):209-222
Introduction: Immune checkpoint inhibitors (ICI) are now a standard of care in the treatment of many cancers leading to durable responses in patients with metastatic disease. These agents are generally well tolerated but may lead to the occurrence of immune-related adverse events (irAEs). As any organ may be affected, clinicians should be aware of the broad range of clinical manifestations and symptoms and keep in mind that toxicities may occur late, at any point along a patient’s treatment course. Although the most common irAEs are rarely severe, some of them may be associated with great morbidity and even become life-threatening. The rate of occurrence, type and severity of irAEs may vary with the type of ICI; thus, grade 3 and 4 irAEs are reported in more than 55% of patients treated with the combination of ipilimumab 3 mg/kg and nivolumab 1 mg/kg.
Area covered: This review presents the management of irAEs resulting from checkpoint blockade, with a focus on rare irAEs.
Expert commentary: With the development of immuno-oncology and the expanding role of ICI, physicians have learnt to diagnose and treat most of the irAEs that can occur. This review provides an overview of current guidelines, previously published studies and our multidisciplinary team based practices. 相似文献
4.
5.
《Mayo Clinic proceedings. Mayo Clinic》2019,94(7):1321-1329
Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been associated with the emergence of a new subset of autoimmune-like toxicities, known as immune-related adverse events. These toxicities differ depending on the agent, malignancy, and individual susceptibilities. Although the skin and colon are most commonly involved, any organ may be affected, including the liver, lungs, kidneys, and heart. Most of these toxicities are diagnosed by excluding other secondary infectious or inflammatory causes. Corticosteroids are commonly used for treatment of moderate and severe immune-related adverse events, although additional immunosuppressive therapy may occasionally be required. The occurrence of immune-related toxicities may require discontinuation of immunotherapy, depending on the specific toxicity and its severity. In this article, we provide a focused review to familiarize practicing clinicians with this important topic given that the use of immune checkpoint inhibitors continues to increase. 相似文献
6.
7.
《慢性疾病与转化医学(英文)》2019,5(1):6-14
Immuno-oncology is a fast evolving field of cancer therapy and immune checkpoint inhibitors (ICIs) are clearly a breakthrough in this field. Cardiotoxicity with conventional anti-cancer therapies has been well studied in the past and clear guidelines for management of these side effects are available in the literature. However, cardiotoxicity with novel agents such as ICIs has been fairly under-reported and/or underestimated and we are yet to formulate clear guidelines for management of these rare side effects. In the last few years, there has been an overall increase in the number of cases of cardiotoxicity related to ICIs. In this literature review, we describe the mechanism of action of the most widely used ICIs and their related cardiotoxicities. The increase in number of case reports about the potential of cardiotoxicities with these novel agents clearly indicates the need for a new insight into the field of cardio-immuno-oncology. 相似文献
8.
肝内胆管癌(ICC)可切除率低,进展期ICC的治疗有效率不高,预后很差。转化治疗在多种晚期肿瘤中有一定的疗效,是目前晚期肿瘤治疗的研究热点。随着对ICC基因组的深入了解和新的治疗药物的开发及组合,基于系统化疗的联合治疗策略,精准靶向治疗,免疫检查点抑制剂等显示出较好的疗效,使得部分进展期ICC病人能降期转化手术,获得长期生存。 相似文献
9.
10.
ABSTRACT